Published: February 3, 2016
Romanian and Egyptian DR programmes, as well as Biotech and Pharma ones, have provided rare bright spots in a market weighed down by Russia’s problems. Alastair O’Dell reports.
This content is only available to our subscribers.
Please click here for details of subscription plans or to request trial access.